Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Ignite Creation Date:
2025-12-25 @ 4:24 AM
Ignite Modification Date:
2025-12-26 @ 3:27 AM
NCT ID:
NCT01287520
Description:
None
Frequency Threshold:
5
Time Frame:
None
Study:
NCT01287520
Study Brief:
A Study of LY2090314 in Patients With Advanced or Metastatic Cancer
Event Groups(If Any):
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| LY 10/Carb 5/Pem 500 (Cohort 1) | * Cycle 1 Day 1 of 28 day cycle: 10 mg LY2090314 administered by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem administered by intravenous infusion followed by AUC 5 mg/mL \* min Carb administered by intravenous infusion followed by 10 mg LY2090314 administered by intravenous infusion. | None | None | 1 | 3 | 3 | 3 | View |
| LY 10/Carb 6/Pem 500 (Cohort 2) | * Cycle 1 Day 1 of 28 day cycle: 10 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 by Pem intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 10 mg LY2090314 by intravenous infusion. | None | None | 3 | 7 | 7 | 7 | View |
| LY 20/Carb 6/Pem 500 (Cohort 3) | * Cycle 1 Day 1 of 28 day cycle: 20 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion. * Cycle 2 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 20 mg LY2090314 by intravenous infusion. | None | None | 3 | 5 | 5 | 5 | View |
| LY 40/Carb 6/Pem 500 (Cohort 4) | * Cycle 1 Day 1 of 28 day cycle: 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 40 mg LY2090314 by intravenous infusion. | None | None | 2 | 7 | 7 | 7 | View |
| LY 80/Carb 6/Pem 500 (Cohort 5) | * Cycle 1 Day 1 of 28 day cycle: 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 80 mg LY2090314 by intravenous infusion. | None | None | 1 | 3 | 3 | 3 | View |
| LY 120/Carb 6/Pem 500 (Cohort 6) | * Cycle 1 Day 1 of 28 day cycle: 120 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem by intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 120 mg LY2090314 by intravenous infusion. | None | None | 1 | 4 | 3 | 4 | View |
| LY 80/Carb 6/Pem 500 + R50 (Cohort 7) | * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 80 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 80 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain. | None | None | 1 | 2 | 2 | 2 | View |
| LY 60/Carb 6/Pem 500 + R50 (Cohort 8) | * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 60 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 60 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain. | None | None | 0 | 5 | 5 | 5 | View |
| LY 40/Carb 6/Pem 500 + R50 (Cohort 9) | * Cycle 1 Day 1 of 28 day cycle: pretreated with 50 mg ranitidine intravenous, 40 mg LY2090314 by intravenous infusion. * Cycle 1 Day 8 of 28 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6mg/mL \* min Carb intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40mmg LY2090314 40 mg by intravenous infusion. * Cycle 2 Day 1 of 21 day cycle: AUC 6 mg/mL \* min Carb by intravenous infusion followed by 500 mg/m\^2 Pem intravenous infusion. * Cycle 3 up to Cycle 9: Day 1 of 21 day cycle: 500 mg/m\^2 Pem by intravenous infusion followed by AUC 6 mg/mL \* min Carb by intravenous infusion followed by 50 mg ranitidine intravenous pretreatment and 40 mg LY2090314 intravenous infusion. Based on I2H-MV-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine was given as a pretreatment to LY2090314 as prophylaxis for stomach pain. | None | None | 1 | 5 | 5 | 5 | View |
Serious Events(If Any):
Serious Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Angina pectoris | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 14.0 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Rectal haemorrhage | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 14.0 | View |
| Pseudomembranous colitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 14.0 | View |
| Dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Back pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Musculoskeletal chest pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Panic attack | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 14.0 | View |
| Dyspnoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Pleural effusion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Deep vein thrombosis | SYSTEMATIC_ASSESSMENT | Vascular disorders | 14.0 | View |
| Chest pain | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
Other Events(If Any):
Other Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Anaemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 14.0 | View |
| Leukocytosis | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 14.0 | View |
| Leukopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 14.0 | View |
| Lymphopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 14.0 | View |
| Neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 14.0 | View |
| Thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 14.0 | View |
| Bundle branch block left | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 14.0 | View |
| Cardiac flutter | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 14.0 | View |
| Palpitations | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 14.0 | View |
| Tinnitus | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | 14.0 | View |
| Asthenopia | SYSTEMATIC_ASSESSMENT | Eye disorders | 14.0 | View |
| Cataract | SYSTEMATIC_ASSESSMENT | Eye disorders | 14.0 | View |
| Eye irritation | SYSTEMATIC_ASSESSMENT | Eye disorders | 14.0 | View |
| Lacrimation increased | SYSTEMATIC_ASSESSMENT | Eye disorders | 14.0 | View |
| Vision blurred | SYSTEMATIC_ASSESSMENT | Eye disorders | 14.0 | View |
| Visual impairment | SYSTEMATIC_ASSESSMENT | Eye disorders | 14.0 | View |
| Vitreous floaters | SYSTEMATIC_ASSESSMENT | Eye disorders | 14.0 | View |
| Abdominal discomfort | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Abdominal distension | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Abdominal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Abdominal pain lower | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Abdominal pain upper | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Ascites | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Diarrhoea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Dyspepsia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Dysphagia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Flatulence | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Haematochezia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Haemorrhoids | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Retching | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Toothache | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 14.0 | View |
| Asthenia | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Catheter site phlebitis | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Chest discomfort | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Chest pain | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Chills | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Influenza like illness | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Infusion site reaction | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Mucosal inflammation | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Nodule | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Oedema peripheral | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | 14.0 | View |
| Drug hypersensitivity | SYSTEMATIC_ASSESSMENT | Immune system disorders | 14.0 | View |
| Hypersensitivity | SYSTEMATIC_ASSESSMENT | Immune system disorders | 14.0 | View |
| Gastroenteritis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 14.0 | View |
| Lung infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 14.0 | View |
| Nasopharyngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 14.0 | View |
| Streptococcal bacteraemia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 14.0 | View |
| Urinary tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 14.0 | View |
| Incision site pain | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 14.0 | View |
| Infusion related reaction | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 14.0 | View |
| Scratch | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 14.0 | View |
| Alanine aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Antineutrophil cytoplasmic antibody increased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Aspartate aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Blood alkaline phosphatase increased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Blood creatinine increased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Blood culture positive | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Blood glucose increased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Blood magnesium decreased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Blood urine present | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Electrocardiogram qt prolonged | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Glomerular filtration rate decreased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Haematocrit decreased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Haemoglobin decreased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Neutrophil count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Weight decreased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| White blood cell count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| White blood cell count increased | SYSTEMATIC_ASSESSMENT | Investigations | 14.0 | View |
| Decreased appetite | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Hypercalcaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Hyperglycaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Hyperkalaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Hyperphosphatasaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Hypoalbuminaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Hypomagnesaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Hyponatraemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Type 2 diabetes mellitus | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 14.0 | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Back pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Bone pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Muscular weakness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Musculoskeletal chest pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Pain in extremity | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 14.0 | View |
| Tumour pain | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 14.0 | View |
| Burning sensation | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Hypogeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Neuropathy peripheral | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Paraesthesia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Peripheral sensory neuropathy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Somnolence | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Syncope | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 14.0 | View |
| Agitation | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 14.0 | View |
| Anxiety | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 14.0 | View |
| Confusional state | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 14.0 | View |
| Insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 14.0 | View |
| Dysuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | 14.0 | View |
| Renal pain | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | 14.0 | View |
| Urinary retention | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | 14.0 | View |
| Vaginal haemorrhage | SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | 14.0 | View |
| Vulvovaginal pruritus | SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | 14.0 | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Dyspnoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Dyspnoea exertional | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Epistaxis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Hiccups | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Hypoxia | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Nasal congestion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Nasal mucosal discolouration | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Oropharyngeal pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Paranasal sinus hypersecretion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Productive cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Pulmonary embolism | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Rhinalgia | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Rhinorrhoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Sinus congestion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Wheezing | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 14.0 | View |
| Alopecia | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Hyperhidrosis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Hypoaesthesia facial | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Night sweats | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Pruritus | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Rash erythematous | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Rash pruritic | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Skin disorder | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 14.0 | View |
| Frontal sinus operation | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | 14.0 | View |
| Flushing | SYSTEMATIC_ASSESSMENT | Vascular disorders | 14.0 | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | 14.0 | View |
| Hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | 14.0 | View |